Epigenomics AG, a German-American cancer molecular diagnostics company, with its U.S. headquaters in Germantown, MD, announced that LabCorp® to offer Epi proColon®, a blood-based test for colorectal cancer screening, in the U.S.
With its U.S. headquarters located within the Germantown Innovation Center, Epigenomics recently announced that its blood-based test for colorectal cancer screening, Epi proColon®, will be available in the U.S. This deal is yet another example of the success of a company in Montgomery County’s Business Innovation Network, specifically in the life sciences incubator, earning significant revenue from the marketplace. “It’s truly hard to express how proud we are when an incubator company makes it through FDA approvals and gets their product to market,” said Sally Sternbach, Acting Director of Montgomery County Department of Economic Development.